Arbutus Biopharma is a Vancouver biotech company focused on therapies for chronic hepatitis B virus infection. The company’s strategy is built around combination drug development and a three-pronged approach to HBV cure: suppress viral DNA, reduce viral antigens, and boost the host immune response. Its portfolio includes RNAi-based therapeutics such as imdusiran and other complementary antiviral approaches.